Posted by Michael Wonder on 13 Dec 2023
Velmanase alfa for the treatment of patients with alfa mannosidosis
13 December 2023 - NICE has published final evidence-based recommendations on the use of velmanase alfa (Lamzede) for treatment of patients with alfa mannosidosis.
Velmanase alfa is recommended as an option for the treatment of patients under 18 years (it can be continued in those who turn 18 while on treatment) with non-neurological signs and symptoms of mild to moderate alfa mannosidosis only if Chiesi provides it according to the commercial arrangement.
